Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics chief financial officer Pierre Gravier reported new equity awards. On January 2, 2026, he received 20,000 restricted stock units, which vest in four equal annual installments starting on January 2, 2027. His direct holdings of common stock totaled 92,449 shares after this grant, including shares previously acquired through the company’s employee stock purchase plan.
On the same date, he was also granted a stock option for 50,000 shares of common stock with an exercise price of $76.74 per share and an expiration date of January 1, 2036. This option vests over four years, with 25% vesting on January 2, 2027 and an additional 6.25% of the original grant vesting at the end of each successive three-month period beginning April 2, 2027.
PTC Therapeutics insider Matthew Klein has filed a Rule 144 notice to sell 5,149 shares of common stock. The planned sale is to be executed through Fidelity Brokerage Services, with an aggregate market value of $396,203.19, and an approximate sale date of January 6, 2026 on NASDAQ. The shares to be sold were acquired on January 5, 2026 through restricted stock vesting as compensation from the issuer.
PTC Therapeutics had 80,288,305 shares of common stock outstanding. Over the prior three months, Matthew Klein sold 3,428 shares for gross proceeds of $271,062.93 on December 2, 2025, and 8,089 shares for $619,921.55 on December 30, 2025. By signing, the seller represents they are not aware of undisclosed material adverse information about the company’s operations.
A holder of common shares of symbol PTCT has filed a Form 144 notice for a planned sale of 1,381 shares through Fidelity Brokerage Services on the NASDAQ. The filing lists an aggregate market value of $106,264.64 for these shares and notes that there were 80,288,305 shares outstanding at the time of the notice. The shares to be sold were acquired on 01/05/2026 through restricted stock vesting from the issuer as compensation, with payment also dated 01/05/2026.
A holder of PTCT common stock has filed a Form 144 notice to sell 1,739 common shares. The shares are planned to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 01/06/2026. The filing notes an aggregate market value for this block of $133,811.88 and shows 80,288,305 common shares outstanding.
The 1,739 shares were acquired on 01/05/2026 via restricted stock vesting from the issuer as compensation. Over the past three months, the same seller, identified as Mark Boulding, has reported multiple sales of PTCT common stock, including transactions on 10/06/2025, 10/07/2025, 11/17/2025, and 01/05/2026 with disclosed gross proceeds for each sale.
An insider of the issuer filed a notice of proposed sale of 1,789 shares of common stock, to be sold through Fidelity Brokerage Services LLC on or about 01/06/2026, with the shares listed on NASDAQ. These shares were acquired on 01/05/2026 through restricted stock vesting from the issuer as compensation.
As context, the filing reports 80,288,305 common shares outstanding. Over the prior three months, Eric Pauwels reported selling common shares in three transactions totaling 40,290; 3,202; and 20,508 shares, for gross proceeds of $3,038,755.33, $240,354.49, and $1,584,387.54, respectively.
Neil G. Almstead filed a notice of proposed sale of 1,279 shares of common stock through Fidelity Brokerage Services LLC, with an approximate sale date of 01/06/2026 on NASDAQ. These shares were acquired as restricted stock vesting from the issuer on 01/05/2026 as compensation.
In the prior three months, Neil G. Almstead sold 35,572 common shares on 11/24/2025 for gross proceeds of 2,852,153.65 and 71,928 common shares on 11/25/2025 for gross proceeds of 6,001,524.59. The notice also includes a representation that he is not aware of undisclosed material adverse information about the issuer.
An insider has filed a notice to sell 2,266 shares of common stock through Fidelity Brokerage Services, with an aggregate market value of $172,216.00. The planned sale is targeted for 01/05/2026 on the NASDAQ market. These shares were acquired on 01/05/2026 via a stock option originally granted on 01/05/2023, and paid for in cash. In the past three months, the same person sold additional common shares in three transactions totaling several thousand shares, while total shares outstanding are 80,288,305.
PTC Therapeutics director reports stock option exercise and share acquisition. A board member exercised a stock option on 12/16/2025 to acquire 24,000 shares of PTC Therapeutics common stock at an exercise price of $30.86 per share. The transaction is coded "M," indicating an option exercise. Following this transaction, the director beneficially owns 155,266 shares of common stock held directly. The exercised option covered 24,000 shares, was noted as currently exercisable, and carries an expiration date of 01/03/2026.
PTC Therapeutics, Inc. director reports option exercise and share sale. On 12/03/2025, the director exercised a stock option for 733 shares of common stock at $46.54 per share and then sold 733 common shares at $78.62 per share. After these transactions, the director directly beneficially owned 6,666 shares of PTC Therapeutics common stock.
The stock option exercised on that date had a conversion price of $46.54 and relates to 733 underlying common shares. Following the transaction, the director held 734 derivative securities (stock options) expiring on 01/02/2035. The filing notes that the transaction was effected under a written Rule 10b5-1 trading plan adopted on March 4, 2025, which is designed to standardize trading and help address trading‑window and insider‑trading concerns.
PTC Therapeutics, Inc. (PTCT) reported insider activity by its Chief Technical Operations Officer. On 11/24/2025, the executive exercised several stock options to buy common stock at exercise prices of $18.01 and $33.02 per share and, on the same date, sold corresponding shares of common stock in multiple transactions at weighted average prices around $80 per share, with specific ranges disclosed for each sale.
The transactions were carried out under a written Rule 10b5-1 trading plan adopted on December 10, 2024, which is intended to provide an affirmative defense for pre-planned trades. Following the reported transactions, the executive beneficially owned 100,625 shares of PTCT common stock directly and an additional 6,179 shares indirectly through a spouse. Certain stock options reported in the filing are noted as currently exercisable, with stated expiration dates in 2028 and 2029.